FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	FGFR3 inhibitor Resistant: C3 – Early Trials FGFR3 inhibitor Resistant : C3	FGFR3 inhibitor Resistant: C3 – Early Trials FGFR3 inhibitor Resistant : C3
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	ARQ 087 Sensitive: C3 – Early Trials ARQ 087 Sensitive : C3	ARQ 087 Sensitive: C3 – Early Trials ARQ 087 Sensitive : C3
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4	pazopanib Sensitive: C4 – Case Studies pazopanib Sensitive : C4
FGFR3 S249C	Lung Adenocarcinoma	FGFR3 S249C	Lung Adenocarcinoma	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	AZ8010 Sensitive: D – Preclinical AZ8010 Sensitive : D	AZ8010 Sensitive: D – Preclinical AZ8010 Sensitive : D
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	PD173074 Sensitive: D – Preclinical PD173074 Sensitive : D	PD173074 Sensitive: D – Preclinical PD173074 Sensitive : D
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D	ABSK091 Sensitive: D – Preclinical ABSK091 Sensitive : D
FGFR3 S249C	Bladder Cancer	FGFR3 S249C	Bladder Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR3 S249C	Bladder Cancer	FGFR3 S249C	Bladder Cancer	LY3076226 Sensitive: D – Preclinical LY3076226 Sensitive : D	LY3076226 Sensitive: D – Preclinical LY3076226 Sensitive : D

FGFR3 S249C

Associations